The clinical efficacy of integrated traditional Chinese and Western medicine treatment of Hospital-acquired pneumonia

被引:0
|
作者
Wu, Chungang [1 ]
机构
[1] First Peoples Hosp Changde, Dept Resp Med, Changde, Hunan, Peoples R China
来源
BIOMEDICAL RESEARCH-INDIA | 2017年 / 28卷 / 09期
关键词
Piperacillin-tazobactam; Tanreqing injection; Hospital-acquired pneumonia; RESISTANT BACTERIA;
D O I
暂无
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Objective: To investigate the clinical efficacy of combination of piperacillin-tazobactam and Tanreqing injection in the treatment of Hospital-Acquired Pneumonia (HAP). Methods: Sixty-four cases of patients with hospital-acquired pneumonia were randomly divided into control and treatment groups. These groups were treated with piperacillin-tazobactam and piperacillin-tazobactam+Tanreqing injection respectively. Clinical symptoms and laboratory parameters of these patients were observed and compared. Results: The clinical and bacteriological assessment efficacy of the two groups was significantly different. The attenuation of clinical symptoms in treatment groups were was better than that in control group. After treatment, the White Blood Cell (WBC) count and C-reaction protein level in the two groups were significantly different. Conclusion: Utilizing the combination of piperacillin-tazobactam and Tanreqing injection to cure acute hospital-acquired pneumonia showed a better clinical efficacy.
引用
收藏
页码:3957 / 3961
页数:5
相关论文
共 50 条
  • [21] Hospital-acquired pneumonia
    Rumbak, MJ
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2002, 23 (05) : 411 - 413
  • [22] Hospital-acquired pneumonia: Epidemiology, etiology, and treatment
    McEachern, R
    Campbell, GD
    INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 1998, 12 (03) : 761 - +
  • [23] Cefiderocol (Fetroja) as a Treatment for Hospital-Acquired Pneumonia
    Plaisance, Connor J.
    Borne, Grant E.
    Daniel, Charles P.
    Wagner, Maxwell J.
    Shelvan, Anitha
    Mathew, Jibin
    Ahmadzadeh, Shahab
    Paladini, Antonella
    Varrassi, Giustino
    Shekoohi, Sahar
    Kaye, Alan D.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (01)
  • [24] PK/PD in the treatment of hospital-acquired pneumonia
    Niki, Yoshihito
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2005, 26 : S35 - S35
  • [25] Ceftobiprole medocaril in the treatment of hospital-acquired pneumonia
    Scheeren, Thomas W. L.
    FUTURE MICROBIOLOGY, 2015, 10 (12) : 1913 - 1928
  • [26] Hospital-Acquired Pneumonia: Pathophysiology, Diagnosis, and Treatment
    Kieninger, Alicia N.
    Lipsett, Pamela A.
    SURGICAL CLINICS OF NORTH AMERICA, 2009, 89 (02) : 439 - +
  • [27] PK/PD in the Treatment of Hospital-acquired Pneumonia
    Niki, Yoshihito
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2005, 26 : S35 - S35
  • [28] Update on the diagnosis and treatment of hospital-acquired pneumonia
    Magiorakos, Annapelle
    Golik, Monica V.
    Lawrence, Kenneth R.
    FORMULARY, 2008, 43 (07) : 250 - +
  • [29] Efficacy and Safety of Tigecycline for Patients with Hospital-Acquired Pneumonia
    Xu, Li
    Wang, Ya-Li
    Du, Shuai
    Chen, Lin
    Long, Li-Hui
    Wu, Yan
    CHEMOTHERAPY, 2015, 61 (06) : 323 - 330
  • [30] Comprehensive risk assessment for hospital-acquired pneumonia: sociodemographic, clinical, and hospital environmental factors associated with the incidence of hospital-acquired pneumonia
    Kim, Bo-Guen
    Kang, Minwoong
    Lim, Jihyun
    Lee, Jin
    Kang, Danbee
    Kim, Minjung
    Kim, Jinhee
    Park, Hyejeong
    Min, Kyung Hoon
    Cho, Juhee
    Jeon, Kyeongman
    BMC PULMONARY MEDICINE, 2022, 22 (01)